Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for human hemoglobinopathies

C E Walsh1, J M Liu, J L Miller

  • 1Clinical Hematology Branch, NHLBI/NIH, Bethesda, Maryland 20892.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.

Haemophilia : the official journal of the World Federation of Hemophilia·2009
Same author

Adeno-associated vectors: are we there yet?

Gene therapy·2008
Same journal

Parasympathomimetic effect of aqueous humor in human eyes with and without chronic simple glaucoma.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
Same journal

Studies on mode of action of streptomycin.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
Same journal

Growth of influenza virus in eggs in the presence of bacterial contamination and streptomycin.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
Same journal

A convenient test animal for the detection of the leukocytosis-promoting factor of exudates.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
Same journal

Preparation of an inactivated tissue culture scrub typhus vaccine.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
Same journal

Studies on scrub typhus; preparation of formalinized vaccines from tissues of infected mice and rats.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
See all related articles

Gene therapy for hemoglobinopathies shows promise using viral vectors. Recombinant adeno-associated virus (AAV) offers advantages like safety and potential for controlled gene expression, despite current limitations.

Area of Science:

  • Gene therapy
  • Molecular biology
  • Virology

Background:

  • Severe hemoglobinopathies require high globin gene expression for treatment.
  • Viral vectors are being explored for gene transfer into human pluripotent stem cells.
  • Retroviral vectors face challenges like rearrangement and poor expression.

Purpose of the Study:

  • To evaluate recombinant adeno-associated virus (AAV) as a potential vector for gene transfer.
  • To compare AAV with other viral vectors for treating hemoglobinopathies.
  • To explore AAV's unique properties for gene therapy applications.

Main Methods:

  • Review of existing literature on viral vector technology for gene transfer.
  • Analysis of the properties of retroviral vectors and recombinant AAV.

Related Experiment Videos

  • Discussion of gene transfer strategies involving cis-acting sequences (LCR) and miniloci.

    • Main Results:

    • Recombinant AAV exhibits non-pathogenicity in humans and selective integration of wild-type AAV into the genome.
    • AAV may offer better control over transferred gene expression.
    • Current limitations of recombinant AAV include packaging capacity and contamination issues.

    Conclusions:

    • Recombinant AAV presents a promising alternative vector for gene transfer due to its safety profile.
    • Further research into AAV's site-specific integration mechanism is crucial for developing safer gene therapy vectors.
    • Understanding DNA recombination in humans can inform future vector development.